OXOS Medical has received the US Food and Drug Administration (FDA) clearance for the MC2 portable X-ray for paediatric imaging.

The clearance enables healthcare providers to provide low-dose, quality X-ray imaging to young patients.

Traditional imaging environments often create anxiety for young patients and stress for their parents.

The MC2 system addresses this by enabling examinations to take place in the same room as the child’s caregivers, reducing the need to separate families during procedures.

OXOS highlights three primary aspects of the MC2’s paediatric capabilities: comfort-driven design, hands-on versatility, and protection for growing bodies.

Its lightweight, wireless construction allows clinicians to perform scans wherever children feel most at ease.

By removing logistical challenges of moving children into specialised rooms, the device also eliminates unnecessary separation from caregivers.

The MC2 system offers hands-free operation using a wireless foot pedal, giving surgeons flexibility during procedures, allowing both hands to assist with patient support or comfort.

Dose control is central in paediatric imaging due to increased sensitivity in children. The MC2 features include an automatic collimator that restricts the X-ray beam to only the necessary area, manual collimation pucks, and a paediatric filter.

This helps ensure high-definition imaging while minimising radiation exposure.

OXOS CEO Evan Ruff said: “For decades, we’ve asked children to adapt to the machine, to hold still in scary rooms away from their parents. That’s backwards. Technology should adapt to the child. MC2 proves that you don’t need an off-base, lead-lined bunker to get a clear, safe diagnosis.”

OXOS co-founder and chief medical officer Dr Gregory Kolovich said: “Radiation exposure is a major concern in paediatric imaging, and it’s something I focus on intently for both my younger patients and my children. MC2 emits low dose while providing the flexibility surgeons need during exams.”